-5%
Bilastine is a highly selective, long-acting, non-sedating antihistamine with strong affinity for H1 receptors—approximately 3 times higher than cetirizine and 5 times higher than fexofenadine. Even at high concentrations, it shows no affinity for 30 other receptor types, including muscarinic, serotonergic, dopaminergic, and noradrenergic receptors, as well as other histamine receptor subtypes (H2, H3, H4).
Bilastine exhibits an excellent safety profile and favorable pharmacokinetic properties. It remains pharmacologically active without undergoing metabolism. The drug is excreted mainly through feces (≈66%) and urine (≈28%), indicating both systemic and non-systemic elimination pathways.
Zilas is indicated for the symptomatic treatment of:
- Allergic rhinoconjunctivitis (both seasonal and perennial)
- Urticaria
It also provides relief from symptoms associated with hay fever, such as sneezing, itching, nasal congestion or discharge, and red or watery eyes.
- The safety and efficacy of this medication in children under 2 years of age have not been established. Limited clinical data are available for ages 2–5 years; hence, use is not recommended in this group.